Measures activity, not value. Not investment advice.
Shares fell 43% in a month even as insiders bought $8.4M, but a private offering was also filed.
WatchSimilar companies trailed their sector by median 17.7 points over 6 months
GoodInstitutional holders rose to 108 from 100 the quarter before, up 8.0%
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
No income statement in this company's recent SEC filings in our data (it may report under IFRS, in another currency, or not file with the SEC).
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$8.4M
bought $8.4M, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+8.0%
108 13F filers vs 100
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
2.7M shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.0
2.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-11%
3.0M shares sold short in the report before, 2.7M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
31%
31% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
38
38 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.6×
38 articles in the last 7 days; its usual week has 5.
Unusual now sharp changes in the last 90 days, compared with its own past
Insider buying $8.4M, 3 insiders
New institutional positions 34, 1.7× a year earlier
Price $6.11 on 20 Nov 2026, -21% over 12 months (12-month range $3.87 to $14.02)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $8.4M in the last 12 months (the 12 months before: $0).Institutional holders (13F filers). 108 13F filers reported holding it in the latest 13F quarter, +59% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Made public in the last 90 days: it had 3 insiders buy $8.4M of its shares on the open market within 30 days (7 filings); it also saw 34 13F filers open a new position in the quarter ended 30 Sep 2026, 1.7× the same quarter last year.
Clustered insider buying: had 3 insiders buy $8.4M of its shares on the open market within 30 days (7 filings) Public on 22 Sep 2026.
Many funds opening a new position: saw 34 13F filers open a new position in the quarter ended 30 Sep 2026, 1.7× the same quarter last year Public on 16 Nov 2026.
Latest records
The names and amounts behind the totals, newest first
Changes and notable records, by the date each became public
16 Nov 2026Institutional holdings change
saw 34 13F filers open a new position in the quarter ended 30 Sep 2026, 1.7× the same quarter last year.
Same quarter last year: 20; its normal quarter is 15.5.
See the evidence
This period
34 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
15.5
Typical spread (median absolute deviation)
3.5
How far from its usual level
+3.6
Same quarter last year
20
History used
2,009 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 15.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
saw 31 13F filers open a new position in the quarter ended 31 Mar 2024, 3.1× the same quarter last year.
Same quarter last year: 10; its normal quarter is 13.
See the evidence
This period
31 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
13
Typical spread (median absolute deviation)
3
How far from its usual level
+4.0
Same quarter last year
10
History used
1,096 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 13
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Not listed: 5 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001833141
Ticker
HELP
Domain
helus.com
Name
CYBIN INC., Helus Pharma Inc.
Wikipedia
Helus Pharma
SEC Form 13F institutional holdings207 data points31 Mar 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)32 records20 Nov 2020 to 1 Sep 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)4 data points31 Mar 2022 to 31 Mar 2025
SEC Form 4 insider transactions9 records, 20 data points9 Sep 2026 to 1 Oct 2026
FINRA short interest (twice monthly)60 data points15 Jan 2026 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)446 data points5 Jan 2026 to 20 Nov 2026
Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026